La cadena de opciones muestra datos clave de las opciones de acciones de Emerald Holding a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Emerald Holding..

Emerald Holding (NYSE:EEX) Bolsa, Cadena de Opciones

EMERALD HOLDING INC

Emerald Holding

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

Movimiento de acciones

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

ASYS

EFXT

GNFT

HYFM

LFVN

MTUS

RSLS

RVSB

STSS

SUNE

VEEE

VERO

WHLR

ReShape Lifesciences firma acuerdo exclusivo con Motion Informatics y dispara sus acciones antes de la apertura de mercado.

Acciones de ReShape Lifesciences (RSLS) se disparan un 82%; Aquí están 20 acciones que se mueven en premercado

Movers_Stocks

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

ADTX

APTO

CSAI

DSGN

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MGOL

MTRX

NESR

NTIC

TNMG

Las acciones de GCL Global suben más del 100% en premercado tras su fusión. Descubre qué otras acciones están en movimiento hoy.

Acciones de GCL Global Holdings (GCL) se disparan un 107%; 20 acciones que se mueven en el premercado

Emerald Holding Inc

Emerald Holding Inc 7% PRF PERPETUAL USD - Ser A

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Buy and maintains $26 price target.

Price Target

Reiteration

Analyst Ratings

Larimar Therapeutics, Inc. - Common Stock

LRMR

Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $26 Price Target

ELAB

PMGC Holdings To Acquire A US-Based CNC Aerospace Manufacturer With A 2024 Revenue Base Of ~$4.5M

Paychex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) will release earnings results for the fourth quarter, before the <a href="https://www.benzinga.com/quote/payx/earnings">opening bell on Wednesday, June 25.</a>
Analysts expect the Rochester, New York-based company to report quarterly earnings at $1.19 per share, on revenue of $1.42 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Paychex founder Thomas Golisano will step down from board of directors, effective after board&#8217;s July, 2025 meeting.
Paychex shares rose 1.4% to close at $151.25 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/payx/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>JP Morgan analyst Tien-Tsin-Huang maintained an Underweight rating and raised the price target from $140 to $148 on June 18, 2025. This analyst has an accuracy rate of 63%.</li>
<li>RBC Capital analyst Ashish Sabadra maintained a Sector Perform rating and boosted the price target from $148 to $165 on June 3, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Ramsey El-Assal maintained an Equal-Weight rating and increased the price target from $140 to $155 on March 31, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Morgan Stanley analyst James Faucette maintained an Equal-Weight rating and raised the price target from $137 to $142 on March 27, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Citigroup analyst Peter Christiansen maintained a Neutral rating and boosted the price target from $145 to $158 on March 27, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying PAYX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PAYX/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-1024x547.png" alt="" class="wp-image-959259" style="width:641px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24033521/image-347.png 1156w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Earnings

PAYX

Paychex Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) saw its stock edge higher in Tuesday&#8217;s premarket session following a significant European breakthrough in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46070261/tilray-medical-receives-italys-first-authorization-from-the-ministry-of-health-to-distribute-medic" rel="noreferrer noopener">medical cannabis sector</a>.
Tilray Medical, a division of Tilray Brands, announced a significant milestone in its European expansion with the introduction of three new medical cannabis flower varieties in Italy.
Through its wholly-owned subsidiary, FL Group, Tilray has become the first company in Italy to receive official authorization from the Ministero della Salute (Italian Ministry of Health) to import and distribute proprietary Tilray Medical-branded medical cannabis flower for therapeutic use.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44870836/vegan-sugar-free-and-now-in-australia-tilrays-edibles-arent-your-average-medical-launch" rel="noreferrer noopener">Vegan, Sugar-Free, And Now In Australia: Tilray&#8217;s Edibles Aren&#8217;t Your Average Medical Launch</a>
The launch includes three medical cannabis varieties, each with distinct cannabinoid compositions: THC 25%, THC 18%, and a balanced THC 9% / CBD 9% formula.
These products are available via pharmacies throughout Italy, supporting healthcare providers in offering more tailored cannabis-based treatment options.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray, emphasized the importance of the milestone, stating it &#8220;underscores the vital role of medical cannabis as a therapeutic medicine for patients in need.&#8221;
She also expressed appreciation for the Italian government&#8217;s support and the regulatory foundation enabling consistent access to cannabinoid therapies.
Tilray continues to scale its reach across Europe with operations in countries including Germany, Portugal, Poland, and the United Kingdom. The company&#8217;s offerings adhere to EU-GMP (Good Manufacturing Practice) certification, which ensures quality and safety standards across its product line.
The expansion into Italy further strengthens Tilray&#8217;s positioning as a frontrunner in the medical cannabis industry, aligning with its goal to empower patients and physicians with reliable and science-driven cannabinoid options.
Price Action: TLRY shares are trading higher by 2.61% to $0.3699 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus" target="_blank" rel="noreferrer noopener">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Photo via Shutterstock

Cannabis

Equities

General

TLRY

Tilray Makes History, First To Import And Sell Branded Medical Cannabis In Italy

Contracts

OSIS

OSI Systems Awarded $14M contract From An International Customer For Cargo And Vehicle Inspection Systems

Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities
SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in the foot and ankle fusion market.
Under the terms of the agreement, SINTX has acquired all intellectual property, product designs, and development assets related to six (6) differentiated foot and ankle implant systems. These designs are backed by clinical development and mechanical testing and a 510(k) pre-submission that is expected to accelerate near-term commercial launch activities. The global ankle fusion market, currently valued at approximately $750.5 million, is expected to grow to $1.38 billion by 2032, representing a CAGR of 9.1%, according to industry research.
"This acquisition is transformative for SINTX by adding a family of FDA-reviewed implants, portfolio of new technologies, and capital, accelerating our shift from R&amp;D to revenue generation and commercial scale," said Eric Olson, CEO of SINTX Technologies. "Additionally, the SiNAPTIC team brings deep expertise in product development, regulatory strategy, and commercialization to support our existing commercial product portfolio—key elements in driving increased value for our shareholders."
As part of the transaction, key members of the SiNAPTIC Surgical executive team and board of directors will join SINTX in the following roles:
<ul>
<li>Chairman of SINTX Clinical Advisory Board, Bryan Scheer, M.D.</li>
<li>Managing Director of Business Development, Hugh Roberts</li>
<li>Chief Commercial Officer, Lisa Marie Del Re, MPE, ATC, NASM-PES</li>
<li>Senior Vice President of Regulatory and Quality Affairs, Brian Hockett</li>
<li>Senior Design Engineer, Basil Tharu, M.S. &nbsp;</li>
</ul>
In consideration for the acquired assets, SINTX issued $750,000 in common shares , priced at $3.465 per share which represents a 10% premium to the closing price of the Company's common stock on Friday, June 20, 2025, along with 325,000 performance-based common stock purchase warrants. The common shares are subject to a six-month lock-up agreement and the Company has committed to file a resale registration statement with the Securities and Exchange Commission registering the resale of the common shares and the common shares issuable on exercise of the common stock purchase warrants. These warrants are exercisable over five years at a strike price of $6.30, and vest upon achieving specific regulatory and commercial milestones, including FDA clearance and revenue targets.
SINTX will manufacture all devices under its FDA-registered and ISO-certified quality system and leverage existing FDA clearances and Master Files to streamline regulatory approvals.
In addition, Dr. Bryan Scheer, Chairman and CEO of SiNAPTIC, will lead a newly formed Clinical Advisory Board to guide ongoing product development and surgeon engagement.

SINT

SINTX Technologies Acquires SiNAPTIC Surgical Assets Including Patented Implants; Issues $750K Shares And 325K Warrants

ASBP

ASBPW

Aspire Biopharma Announces Last Patient Dosed In Phase 1 Single-Center Clinical Study Of Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation; Topline Results Expected Mid Q3 2025

Guggenheim analyst John Heinbockel reiterates Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) with a Buy and maintains $36 price target.

Guggenheim Reiterates Buy on Life Time Group Hldgs, Maintains $36 Price Target

JP Morgan analyst Tomohiko Sano initiates coverage on Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) with a Overweight rating and announces Price Target of $170.

Initiation

ALLE

JP Morgan Initiates Coverage On Allegion with Overweight Rating, Announces Price Target of $170

Guggenheim analyst Michael Schmidt reiterates ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and maintains $45 price target.

AVBP

Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target

DSS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSS#NYSE">DSS</a>) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that its subsidiary, Impact BioMedical Inc. ("Impact"), has entered into a definitive merger agreement (the "Merger Agreement") with Dr. Ashleys Limited ("Dr. Ashleys"), a global pharmaceutical company.
Under the terms of the agreement, Dr. Ashleys will acquire Impact through a reverse merger that will result in a newly formed combined entity (the "PubCo") traded on the NYSE American under the name "Dr Ashleys Limited."
This strategic transaction marks an important milestone not only for Impact, but also for DSS, as it reflects a successful outcome in the overall Company strategy to unlock value across the portfolio and for its shareholders by advancing key subsidiaries toward independent public listings and/or other exit opportunities.

DSS' Impact BioMedical Enters Into Definitive Merger Agreement With Dr. Ashleys

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models
Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use
FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1b Dose Finding study of its Auger emitting radiopharmaceutical, CLR 125, for the treatment of relapsed TNBC. CLR 125 is an iodine-125 Auger-emitting drug candidate targeting solid tumors, such as triple negative breast, lung and colorectal cancers.

Biotech

CLRB

Cellectar Biosciences Submits FDA Protocol For Phase 1b Study Of CLR 125 In Relapsed Triple Negative Breast Cancer

Guggenheim analyst Michael Morris reiterates Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and maintains $165 price target.

RDDT

Guggenheim Reiterates Buy on Reddit, Maintains $165 Price Target

Primech AI Pte. Ltd. ("Primech AI" or the "Company"), a subsidiary of Primech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>), today announced the signing of a strategic partnership with Hong Kong-based ReMining Ai Ltd to expand the deployment of its revolutionary HYTRON autonomous <a href="https://www.globenewswire.com/Tracker?data=iZ7fObqGU6ZnGNY5lLVfIy5XGRRitwii5kKoE1rMQzpE2lSCgnlvg_7isAYr1wcV4XtpG54CFPtbVVVp0CnWMA97q_jZfi0z6E4P3DZMylHdZAUmCQbYfHh1Y5ml1MI6ScUsyTbB6aqyb1b6hHM_wA==">bathroom cleaning robot</a> to the Hong Kong market.
The companies formally established their collaboration through a signed Memorandum of Understanding (MOU), creating a framework for ReMining Ai Ltd to serve as Primech AI's authorized agent in Hong Kong for two years.

Global

PMEC

Primech AI Partners With ReMining Ai To Launch HYTRON Autonomous Bathroom Cleaning Robot In Hong Kong

ONDS

Ondas Holdings' American Robotics Partners With Mistral, Focusing On Joint Marketing, Sales, And Integration Of Optimus Drone System And Iron Drone Raider Into US Defense And Homeland Security Markets

Quoin Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company's lead asset, QRX003, for the treatment of Netherton Syndrome.
The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. It follows earlier regulatory recognition by the European Medicines Agency (EMA), which granted Orphan Drug Designation to QRX003 in May 2025.

QNRX

Quoin Pharmaceuticals Receives FDA Rare Pediatric Disease Designation For QRX003 To Treat Netherton Syndrome

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $50 to $68.

CDTX

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $68

Journey Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000&#xAE; Index and the broad-market Russell 3000&#xAE; Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution.

DERM

Journey Medical To Join Russell 2000 And Russell 3000 Indexes, Effective After The Close Of U.S. Equity Markets On June 27, 2025

AMPG

AmpliTech Group's 5G Division Receives Follow On Order Over $1M As Part Of LOI For 5G ORAN Radios

Four-year award leverages BlackSky's real-time, AI-driven monitoring services for automated object and pattern-of-life change detection at military and economic facilities worldwide
BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) won a more than $24 million, four-year, National Geospatial-Intelligence Agency (NGA) Luno A Facility Operational Monitoring (FOMO) delivery order for global monitoring of military and economic facilities. As part of the order, BlackSky has received an initial base and surge option award of $2 million.

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Technology Bags Over $24M, 4-Yr, National Geospatial-Intelligence Agency Luno A FOMO Delivery Order For Global Monitoring Of Military And Economic Facilities

Press Releases

Emerald Completes Refinancing and Upsizing of $515 Million Term Loan and Revolver Extension

Emerald Announces Date for Fourth Quarter and Full Year 2024 Financial Results Conference Call; Declares Quarterly Dividend

Emerald Reports Fourth Quarter and Full Year 2024 Financial Results

Emerald Agrees to Acquire Global Portfolio of Experiential and Luxury Travel Industry B2B Events

Emerald Acquires Insurtech Insights, a Global Leader in Insurance Technology Conferences and Innovation Programs

Emerald Holding, Inc. Appoints Erica Bartsch as Executive Vice President, Strategy and Communications

Comments

Emerald Holding

Emerald Holding (EEX) Opciones

Emerald Holding (NYSE:EEX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL